14th International Conference on Malignancies in AIDS and Other Acquired Immunideficiencies

155 Pages·2013·3.89 MB·English

by  National Cancer Institute

14th International
Conference on
Malignancies in AIDS
and Other Acquired
Immunodeficiencies
November 12-13, 2013
Lister Hill Auditorium
NIH Main Campus
Bethesda, Maryland

14th International
Conference on
Malignancies in
AIDS and Other
Acquired
Immunodeficiencies
November 12-13, 2013
Lister Hill Auditorium
NIH Main Campus
Bethesda, Maryland

Program

November 12

8:00 a.m. - 8:15 a.m. Poster Setup (posters to stay up for the entire meeting)

8:15 a.m. - 8:30 a.m. Opening Remarks: Day 1
Robert Yarchoan, M.D.
Office of HIV and AIDS Malignancy
National Cancer Institute, NIH, USA

Geraldina Dominguez, Ph.D.
Office of HIV and AIDS Malignancy
National Cancer Institute, NIH, USA

8:30 a.m. - 9:30 a.m. HPV Vaccines
Moderator: T-C Wu, M.D., Ph.D.
Johns Hopkins University, USA

8:30 a.m. - 9:00 a.m. Plenary: L2 as a Target for Prophylactic Human Papillomavirus

Vaccination

Richard Roden, Ph.D.

Johns Hopkins University, USA

9:00 a.m. - 9:30 a.m. Plenary: HPV Vaccination in HIV-Infected Men and Women
Joel Palefsky, M.D.

University of California, San Francisco, USA

9:30 a.m. - 10:15 a.m. Oral HPV
Moderator: Isaac R. Rodriguez-Chavez, Ph.D.
National Institute of Dental and Craniofacial Research, NIH, USA

9:30 a.m. - 9:45 a.m. HIV-Induced Epithelial-Mesenchymal Transition in Oral Mucosal
Epithelial Cells Facilitates HPV Infection
Sharof M. Tugizov, D.V.M., Ph.D., D.Sc.

University of California, San Francisco, USA

9:45 a.m. - 10:00 a.m. HIV-Related Immunosuppression Is Associated With Higher Incidence of
Oral HPV, But Not Oral HPV Clearance
Daniel C. Beachler, M.S.P.H.

Johns Hopkins University, USA

10:00 a.m. - 10:15 a.m. HIV Tat Increases HPV16 Infectivity Independent of Oral Keratinocyte
Terminal Differentiation
Jennifer Webster-Cyriaque, D.D.S., Ph.D.

The University of North Carolina at Chapel Hill, USA

10:15 a.m. - 10:45 a.m. Break and Poster Session

- 1 ­
10:45 a.m. - 12:15 p.m. Pathogens and Host Interactions
Moderator: Corey Casper, M.D., M.P.H.
Fred Hutchinson Cancer Research Center, USA

10:45 a.m. - 11:15 a.m. Plenary: Potential Role of Graft-Versus-Host Reaction in Reducing the
HIV-1 Reservoir
Daniel R. Kuritzkes, M.D.

Brigham and Women’s Hospital, USA

11:15 a.m. - 11:30 a.m. Variation in Viral Gene Expression Distinguishes Two Subtypes of
Kaposi Sarcoma
Dirk P. Dittmer, Ph.D.

The University of North Carolina at Chapel Hill, USA

11:30 a.m. - 11: 45 a.m. Characterization of HHV-8 Gene Expression in Kaposi Sarcoma Tumors
and Correlation With Clinical Presentation and Outcomes
Warren Phipps, M.D., M.P.H.

Fred Hutchinson Cancer Research Center, USA

11:45 a.m. - 12 noon Prevalent High-Risk HPV Infection and Vaginal Microbiota in Nigerian
Women
Clement A. Adebamowo, M.D.

Institute of Human Virology

University of Maryland School of Medicine, Baltimore, USA

12 noon - 12:15 p.m. Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome
Among HIV-Infected Individuals in the Center for AIDS Research
Network of Integrated Clinical Systems
Satish Gopal, M.D.

The University of North Carolina at Chapel Hill, USA

12:15 p.m. - 1:45 p.m. Lunch

12:45 p.m. - 1:45 p.m. Poster Session (Day 1 presenters to stand by their posters)

1:45 p.m. - 2:45 p.m. Cancer Burden in Low and Middle Income Countries
Moderator: Sam Mbulaiteye, M.D.
National Cancer Institute, NIH, USA

1:45 p.m. - 2:15 p.m. Plenary: Harnessing Cancer Registry and HIV Databases in Low and
Middle Income Countries
Diego Serraino, M.D.

IRCCS Centro di Riferimento Oncologico, Italy

2:15 p.m. - 2:45 p.m. Plenary: HIV and Cancer Survival in Uganda
Anna E. Coghill, Ph.D., M.P.H.

National Cancer Institute, NIH, USA

2:45 p.m. - 3:30 p.m. Break and Poster Session (Lister Hill cafeteria closes at 3:00 p.m.)

- 2 ­
3:30 p.m. - 5:30 p.m. KSHV Biology
Moderators: Denise Whitby, Ph.D.
National Cancer Institute, NIH, USA

Dirk P. Dittmer, Ph.D.

The University of North Carolina at Chapel Hill, USA

3:30 p.m. - 3:45 p.m. Kaposi Sarcoma Herpesvirus (KSHV) vFLIP Induces Systemic Endothelial
Proliferation and a Proinflammatory Phenotype In Vivo
Gianna Ballon, M.D.

Weill Cornell Medical College, USA

3:45 p.m. - 4:00 p.m. Human Herpesvirus 8 Infection Induces Polyfunctional B Lymphocytes
Producing Cytokines and Chemokines That Drive Kaposi’s Sarcoma
Charles R. Rinaldo, Ph.D.

University of Pittsburgh, USA

4:00 p.m. - 4:15 p.m. Kaposi Sarcoma-Associated Human Herpesvirus (KSHV) Latency-
Associated Nuclear Antigen (LANA) Undergoes Cleavage by Caspases
Following Exposure of Cells to Oxidative Stress
David A. Davis, Ph.D.

National Cancer Institute, NIH, USA

4:15 p.m. - 4:30 p.m. Regulation of Kaposi Sarcoma Herpesvirus (KSHV) Encoded Viral
Interleukin 6 (vIL-6) by X-Box Binding Protein 1 (XBP-1)
Duosha Hu, M.D., Ph.D.

National Cancer Institute, NIH, USA

4:30 p.m. - 4:45 p.m. RNA-Independent Activation of RIG-I by Deamidation
Pinghui Feng, Ph.D.

University of Southern California, USA

4:45 p.m. - 5:00 p.m. KSHV-Dependent Activation of Platelet Derived Growth Factor Receptor
Signaling Is an Oncogenesis Driver and a Therapeutic Target in Kaposi’s
Sarcoma
Enrique A. Mesri, Ph.D.

University of Miami, USA

5:00 p.m. - 5:15 p.m. Using Proteomics to Understand Human Target Genes of KSHV

MicroRNAs

Joseph M. Ziegelbauer, Ph.D.

National Cancer Institute, NIH, USA

5:15 p.m. - 5:30 p.m. KS-Detect: A Complete “Sample-In, Answer-Out” Solution to the

Diagnosis of Kaposi’s Sarcoma

Ethel Cesarman, M.D., Ph.D.

Weill Cornell Medical College, USA

5:30 p.m. End of Day 1

- 3 ­
November 13

8:00 a.m. - 8: 15 a.m. Poster Viewing

8:15 a.m. - 8:20 a.m. Welcoming Remarks: Day 2
Geraldina Dominguez, Ph.D.
National Cancer Institute, NIH, USA

8:20 a.m. - 8:30 a.m. Fogarty International Center’s HIV Research Training Program
Jeanne McDermott, Ph.D., M.P.H.
Fogarty International Center, NIH, USA

8:30 a.m. - 9:30 a.m. Hepatitis C Virus
Moderator: Ren Sun, Ph.D.
University of California, Los Angeles, USA

8:30 a.m. - 9:00 a.m. Plenary: Hepatitis C and Hepatocellular Carcinoma: New Model
Systems and Insights Into Pathogenesis
Stanley M. Lemon, M.D.

The University of North Carolina at Chapel Hill, USA

9:00 a.m. - 9:30 a.m. Plenary: Natural Courses and Management of Chronic Viral Hepatitis B
or C in HIV-Infected Patients
Pei-Jer Chen, M.D., Ph.D.

National Taiwan University Hospital, Taiwan

9:30 a.m. - 10:15 a.m. Clinical Trials and Correlative Studies
Moderator: Alexandra M. Levine, M.D.
City of Hope National Medical Center, USA

9:30 a.m. - 9:45 a.m. Results of a Phase I Study of Lenalidomide in Patients With AIDS-
Associated Kaposi Sarcoma (AMC 070)
Kelly Shimabukuro, M.D.

University of California, San Diego, USA

9:45 a.m. - 10:00 a.m. Antiretrovirals for Kaposi’s Sarcoma (ARKS): A Randomized Trial of
Protease Inhibitor-Based Antiretroviral Therapy for AIDS-Associated
Kaposi’s Sarcoma in Sub-Saharan Africa
Jeffrey N. Martin, M.D., M.P.H.

University of California, San Francisco, USA

10:00 a.m. - 10:15 a.m. Studies in Primary Cultures of Human Hepatocytes and Computer
Simulations Provide Guidance for Dosing of Anticancer Drugs in
Patients Treated With HAART Drugs
Raman Venkataramanan, Ph.D.

University of Pittsburgh, USA

10:15 a.m. - 10:45 a.m. Break and Poster Session

- 4 ­
10:45 a.m. - 12:15 p.m. EBV and Lymphomagenesis
Moderators: Elliott D. Kieff, M.D., Ph.D.
Harvard Medical School, USA

Richard F. Ambinder, M.D., Ph.D.

Johns Hopkins University School of Medicine, USA

10:45 a.m. - 11:15 a.m. Plenary: Immune Activation and Inflammation Biomarkers and Risk for
AIDS-NHL
Otoniel Martinez-Maza, Ph.D.

University of California, Los Angeles, USA

11:15 a.m. - 11:30 a.m. Differential Expression and Prognostic Utility of Immunophenotypic
Markers in Diffuse Large B-cell Lymphoma From Patients With and
Without HIV Infection
Chun R. Chao, Ph.D.

Kaiser Permanente Southern California, USA

11:30 a.m. - 11:45 a.m. Targeting Sphingosine Kinase Induces Apoptosis and Regression of
Virus-Associated Lymphoma In Vivo
Chris M. Parsons, M.D.

Louisiana State University Health Sciences Center, USA

11:45 a.m. - 12 noon The HIV-1 Matrix Protein and AIDS-Related Lymphoma
Mark K. Lafferty, Ph.D.

Institute of Human Virology, University of Maryland School of Medicine, USA

12 noon - 12: 15 p.m. Characterizing Survival in the Absence of LMP1-Mediated NFκB
Signaling in the Model of EBV-Driven AIDS Lymphoma
Alexander Price

Duke University, USA

12:15 p.m. - 2:00 p.m. Lunch

1:00 pm. - 2:00 p.m. Poster Session (Day 2 presenters to stand by their posters)

2:00 p.m. - 2:45 p.m. Lung Cancer
Moderator: Missak Haigentz, M.D.
Albert Einstein College of Medicine, USA

2:00 p.m. - 2:30 p.m. Plenary: Chronic Inflammation and Lung Cancer
Anil K. Chaturvedi, Ph.D.

National Cancer Institute, NIH, USA

2:30 p.m. - 2:45 p.m. Inflammatory Biomarkers and CT-Detected Lung Nodules: Potential
Implications for Lung Cancer Screening of HIV-Infected Patients
Kristina Crothers, M.D.

University of Washington School of Medicine, USA

2:45 p.m. -3:30 p.m. Break and Poster Session (Lister Hill cafeteria closes at 3:00 p.m.)

- 5 ­
3:30 p.m. - 5: 30 p.m. Epidemiological Studies
Moderators: Michael J. Silverberg, Ph.D., M.P.H.
Kaiser Permanente, USA

Eric Engels, M.D., M.P.H.
National Cancer Institute, NIH, USA

3:30 p.m. - 3:45 p.m. Applying the Methods of Causal Inference to HIV-Associated
Malignancies: Estimation of the Impact of Antiretroviral Therapy on
Kaposi’s Sarcoma Incidence in East Africa via a Nested New User
Cohort Analysis
Aggrey S. Semeere, M.D.
University of California, San Francisco, USA

3:45 p.m. - 4:00 p.m. Impact of Kaposi’s Sarcoma on Survival Among HIV Infected Adults in
Africa in the Era of Antiretroviral Therapy
Stephen B. Asiimwe, M.D. ‐
Mbarara Regional Referral Hospital, Mbarara, Uganda

4:00 p.m. - 4:15 p.m. Prevalence of HIV Infection Among U.S. Hodgkin Lymphoma Cases
Meredith S. Shiels, Ph.D., M.S.
National Cancer Institute, NIH, USA

4:15 p.m. - 4:30 p.m. Risk of Non-Hodgkin Lymphoma Subtypes in People Infected With HIV
During the HAART Era
Todd M. Gibson, Ph.D.
National Cancer Institute, NIH, USA

4:30 p.m. - 4:45 p.m. Time Trends of Cancer Mortality Rates Among Men in the Veterans
Aging Cohort Study
Robert Dubrow, M.D., Ph.D.
Yale School of Public Health, USA

4:45 p.m. - 5:00 p.m. Epidemiologic Contributions to Recent Cancer Trends Among HIV-
Infected People in the United States
Hilary A. Robbins, M.S.P.H.
National Cancer Institute, NIH, USA

5:00 p.m. - 5:15 p.m. Cancer Treatment Disparities in HIV-Infected Individuals in the United
States
Gita Suneja, M.D.
University of Pennsylvania, USA

5:15 p.m. Meeting Adjourned

- 6 ­